⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826883 | 1.00 | — | — | |
| SCHEMBL29490275 | 0.75 | — | — | |
| SCHEMBL21580811 | 0.75 | — | — | |
| SCHEMBL2483892 | 0.75 | — | — | |
| SCHEMBL802806 | 0.75 | — | — | |
| SCHEMBL29843421 | 0.75 | — | — | |
| SCHEMBL3015741 | 0.75 | — | — | |
| SCHEMBL31527977 | 0.75 | — | — | |
| SCHEMBL8062044 | 0.75 | — | — | |
| SCHEMBL17264660 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939829-B | Synthetic method of aryl trifluoromethyl thioether | 武汉药明康德新药开发有限公司 | 2023-02-21 | — | — | CN | claimed |
| CN-112939829-A | Synthetic method of aryl trifluoromethyl thioether | 武汉药明康德新药开发有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-102898358-A | Preparation method of fluoropyridine compounds | SHANGHAI TITAN TECHNOLOGY CO LTD | 2013-01-30 | — | — | CN | claimed |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4701735-A1 | HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR | Nested Therapeutics, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250361241-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2025-11-27 | — | — | US | disclosed |
| EP-4635944-A1 | 2-AZABICYCLO[3.1.1]HEPTANE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4618974-A1 | OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| EP-2178858-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2011-12-28 | — | — | EP | disclosed |
| CN-101952274-A | Non-nucleoside reverse transcriptase inhibitor | MERCK & CO INC | 2011-01-19 | — | — | CN | disclosed |
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2222661-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009067166-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |